



Prescribing Outpatient Treatments for COVID-19

Outpatient treatment options for mild to moderate COVID-19 infection at **high risk for progression to severe COVID-19** continue to expand. The Food and Drug Administration granted emergency use authorization (EUA) for outpatient use of infused drugs Sotrovimab (mAb) and Remdesivir. The FDA also granted EUA for oral COVID-19 antivirals, Paxlovid and Molnupiravir. HAP supports access to these highly effective oral treatments. **Prior authorization is not required and there is no member copay or cost share.** Below is important information regarding prioritization of these medications.


State of Michigan Prioritization Framework and Eligibility

The Michigan Department of Health and Human Services published the guidance below.

Outpatient therapy now available for those with COVID-19. Supplies may be limited.
Eligibility guidelines ensure those with the highest risks have priority access to treatments.

Those at highest risk	Treatment window after symptoms appear:	Paxlovid PO	Sotrovimab IV	Remdesivir IV	Molnupiravir PO
		5 days	10 days	7 days	5 days
<ul style="list-style-type: none"> 75+ years old and not up to date* Moderately or severely immunocompromised regardless of vaccine status 		✓	✓	✓	✓ <small>If other therapies not available or appropriate</small>
		✓	✓	✓	✓ <small>If other therapies not available or appropriate</small>
<ul style="list-style-type: none"> 65-74 years old and not up to date* with MI priority risk factor** Pregnant and not up to date* 		✓	✓	✓	✓ <small>If other therapies not available or appropriate</small>
		✓	✓	✓	✓ <small>If other therapies not available or appropriate</small>
<ul style="list-style-type: none"> 65-74 years old and not up to date* Under 65 years old and not up to date* with MI priority risk factor** 		✓	✓	✓	✓ <small>If other therapies not available or appropriate</small>
		✓	Not currently eligible	Not currently eligible	✓ <small>If other therapies not available or appropriate</small>
<ul style="list-style-type: none"> 75+ years old and up to date* 65-74 years old and up to date* with MI priority risk factor** 		✓	Not currently eligible	Not currently eligible	✓ <small>If other therapies not available or appropriate</small>
		Not currently eligible	Not currently eligible	Not currently eligible	✓
<ul style="list-style-type: none"> 65-74 years old and up to date* with <u>CDC risk factors</u> 65-74 years old and up to date* Younger than 65 years old and up to date* with <u>CDC risk factors</u> 		Not currently eligible	Not currently eligible	Not currently eligible	✓
		Not currently eligible	Not currently eligible	Not currently eligible	✓

*Up to date means a person has received all recommended COVID-19 vaccines, including booster dose(s) when eligible (bit.ly/CDCStayUpToDate).
**MI priority risk factors include: Obesity (Body Mass Index >35), chronic respiratory disease, pregnancy (note: in pregnancy, molnupiravir should not be used and Paxlovid and remdesivir should be used with caution when sotrovimab is unavailable), chronic kidney disease (special considerations with Paxlovid), cardiovascular disease, and diabetes.



Clinical Risk for Patient Consideration

According to The Centers for Disease Control and Prevention (CDC), **moderately or severely immunocompromised** patients continue to be at highest risk and can be offered treatment **regardless of vaccination status**. Moderately or severely immunocompromised patients have any of the following:

- Active cancer treatment for tumors or cancers of the blood
- Organ transplant and taking medicine to suppress the immune system
- Stem cell transplant within the last 2 years or taking medicine to suppress the immune system
- Moderate or severe primary immunodeficiency
- Advanced or untreated HIV infection
- Active treatment with high-dose corticosteroids or other drugs that may suppress immune response

Age Considerations with Michigan Priority Risk Factors

Due to limited supply, the state of Michigan created a narrow prioritization framework for eligibility. **MI priority risk factors** include obesity (BMI > 35), chronic respiratory disease, pregnancy, chronic kidney disease, cardiovascular disease, and diabetes. Patients **any age with MI priority risk factors** and not fully vaccinated, including booster dose, are eligible for treatment as follows:

- Paxlovid, Remdesivir, and Sotrivomab: For patients age 12 and older (>40 kg)
- Molnupiravir: For patients age 18 and older

Resources

More information can be found [here](#).